产品
编 号：F459327
分子式：C8H16O5
分子量：192.21
分子式：C8H16O5
分子量：192.21
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 78606-80-1
产品详情
生物活性：
BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2). BML-111 has antiangiogenic, antitumor and anti-inflammatory properties.
体内研究：
BML-111 (1 mg/kg; intraperitoneal injection; for 15 days; male Imprinting Control Region mice) treatment suppresses tumor-related angiogenesis and tumor growth in vivo. BML-111 also enhances the in situ apoptosis while inhibiting macrophage infiltration in tumor tissue.BML-111 protects LPS-induced acute lung injury and LPS/D-GalN-induced acute liver injury. BML-111 represses the activity of ACE, but increases the activity of ACE2. BML-111 decreases the expression levels of ACE, AngII, and AngII type 1 receptor (AT1R), meanwhile increases the levels of ACE2, angiotensin-(1-7) (Ang-1-7), and Mas.Animal Model:Male Imprinting Control Region mice (5-6-week-old,18-22 g) injected with H22 cells
Dosage:1 mg/kg
Administration:Intraperitoneal injection; injected 5 minutes before and 4 hours after H22 cell inoculation, then every 12 hours for 2 consecutive days, then daily in an additional 3 days and every other day for the last 10 days
Result:Suppressed tumor-related angiogenesis and tumor growth in vivo.
体外研究：
In H22 cells, BML-111 inhibits the production of vascular endothelial growth factor and reduces hypoxia-inducible factor-1α level.BML-111 inhibits leukotriene B4-induced cellular migration with an IC50 of 5 nM.
BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2). BML-111 has antiangiogenic, antitumor and anti-inflammatory properties.
体内研究：
BML-111 (1 mg/kg; intraperitoneal injection; for 15 days; male Imprinting Control Region mice) treatment suppresses tumor-related angiogenesis and tumor growth in vivo. BML-111 also enhances the in situ apoptosis while inhibiting macrophage infiltration in tumor tissue.BML-111 protects LPS-induced acute lung injury and LPS/D-GalN-induced acute liver injury. BML-111 represses the activity of ACE, but increases the activity of ACE2. BML-111 decreases the expression levels of ACE, AngII, and AngII type 1 receptor (AT1R), meanwhile increases the levels of ACE2, angiotensin-(1-7) (Ang-1-7), and Mas.Animal Model:Male Imprinting Control Region mice (5-6-week-old,18-22 g) injected with H22 cells
Dosage:1 mg/kg
Administration:Intraperitoneal injection; injected 5 minutes before and 4 hours after H22 cell inoculation, then every 12 hours for 2 consecutive days, then daily in an additional 3 days and every other day for the last 10 days
Result:Suppressed tumor-related angiogenesis and tumor growth in vivo.
体外研究：
In H22 cells, BML-111 inhibits the production of vascular endothelial growth factor and reduces hypoxia-inducible factor-1α level.BML-111 inhibits leukotriene B4-induced cellular migration with an IC50 of 5 nM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备